Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Oktober 2020

Planlagt Fastgjort Låst Flyttet Genmab
767 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #265

    anything about filing for approval this year with amivantamab or anything about the new Duobody in the clinic?

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #266

      I think 10:50 points to amivantamab filing in Q4?

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #267

        Beyond that i can only find JNJ-7957 (BCMA/CD3), JNJ-7564 (GPRC5D/CD3) for planned filing 2020-2023

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote on sidst redigeret af
          #268

          10:50 E L - ohh yes sorry !

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #269

            Thx E L

            1 Reply Last reply
            0
            • BulderB Offline
              BulderB Offline
              Bulder
              wrote on sidst redigeret af
              #270

              I didn't realize we were that close to an amivantamab filing.

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #271

                Its going to be fun to see milestones for filing and approval to get a feeling about how backloaded these Duobody deals are

                1 Reply Last reply
                0
                • bongobobB Offline
                  bongobobB Offline
                  bongobob
                  wrote on sidst redigeret af
                  #272

                  Meget informativt om Amivantamab. 6-12 md approval...moving to 1.line... Beklager hvis den har været linket. https://www.docwirenews.com/hematology-oncology/amivantamab-plus-lazertinib-combo-show-promising-results-at-esmo-2020/

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #273

                    SITC ID: 561
                    DuoBody®-PD-L1×4-1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4-1BB co-stimulation https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13906&CONF=SITC20&ssoOverride=OFF&CKEY=

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      GeorgeBest
                      wrote on sidst redigeret af
                      #274

                      Thanks E L and bongobob

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #275

                        SITC ID: 412
                        First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in patients with advanced solid tumors https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13347&CONF=SITC20&ssoOverride=OFF&CKEY=

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          GeorgeBest
                          wrote on sidst redigeret af
                          #276

                          12:40 I like the phrase “superior”

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #277

                            Conclusions DuoBody-PD-L1×4-1BB demonstrated biologic activity and a manageable safety profile. Encouraging early clinical activity across different dose levels was observed in a heavily pretreated population with advanced solid tumors, including those resistant to prior immunotherapy or typically less sensitive to ICIs. Expansion cohorts of patients for whom DuoBody-PD-L1×4-1BB treatment could be relevant and biologically sound have started enrollment. Updated data will be presented.

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #278

                              Disease control, including stable disease at first assessment and partial responses in triple-negative breast cancer, ovarian cancer, and immune checkpoint inhibitor (ICI)–pretreated NSCLC, occurred in 40/61 patients (65.6%).

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #279

                                SITC ID: 704
                                Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13592&CONF=SITC20&ssoOverride=OFF&CKEY=

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #280

                                  Opdaterede salgstal på Darzalex. https://www.proinvestor.com/boards/87573#87574

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #281

                                    SITC ID: 617
                                    Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13984&CONF=SITC20&ssoOverride=OFF&CKEY=

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #282

                                      SITC ID: 621
                                      A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13536&CONF=SITC20&ssoOverride=OFF&CKEY= (camidanlumab tesirine (ADCT-301))

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        Plimsoller
                                        wrote on sidst redigeret af
                                        #283

                                        Tak Helge. Projekteret i den øveste del af intervallet. Hvis det ender sådan, så kan vi ikke klage 🙂

                                        1 Reply Last reply
                                        0
                                        • BulderB Offline
                                          BulderB Offline
                                          Bulder
                                          wrote on sidst redigeret af
                                          #284

                                          Tak bongo. Så amivantamab 100% RR i første linje (få pts ganske vist) og godkendelse om et par år.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger